These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19584228)

  • 21. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
    Rapisarda A; Melillo G
    Oncogene; 2007 Oct; 26(48):6875-84. PubMed ID: 17496931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells.
    Kim MH; Jeong YJ; Cho HJ; Hoe HS; Park KK; Park YY; Choi YH; Kim CH; Chang HW; Park YJ; Chung IK; Chang YC
    Oncol Rep; 2017 Feb; 37(2):777-784. PubMed ID: 27959445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
    Takano S; Kamiyama H; Mashiko R; Osuka S; Ishikawa E; Matsumura A
    J Neurooncol; 2010 Sep; 99(2):177-85. PubMed ID: 20066473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
    Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
    Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
    Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
    Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
    Newcomb EW; Ali MA; Schnee T; Lan L; Lukyanov Y; Fowkes M; Miller DC; Zagzag D
    Neuro Oncol; 2005 Jul; 7(3):225-35. PubMed ID: 16053697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
    Yin S; Kaluz S; Devi NS; Jabbar AA; de Noronha RG; Mun J; Zhang Z; Boreddy PR; Wang W; Wang Z; Abbruscato T; Chen Z; Olson JJ; Zhang R; Goodman MM; Nicolaou KC; Van Meir EG
    Clin Cancer Res; 2012 Dec; 18(24):6623-33. PubMed ID: 22923450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
    Pourgholami MH; Cai ZY; Badar S; Wangoo K; Poruchynsky MS; Morris DL
    BMC Cancer; 2010 Apr; 10():143. PubMed ID: 20398289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of small interference RNA targeting HIF-1alpha mediated by rAAV combined L: -ascorbate on pancreatic tumors in athymic mice.
    Chen C; Sun J; Liu G; Chen J
    Pathol Oncol Res; 2009 Mar; 15(1):109-14. PubMed ID: 18509748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.
    Matsumoto K; Obara N; Ema M; Horie M; Naka A; Takahashi S; Imagawa S
    Cancer Sci; 2009 Sep; 100(9):1639-47. PubMed ID: 19575748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1.
    Chou CW; Wang CC; Wu CP; Lin YJ; Lee YC; Cheng YW; Hsieh CH
    Neuro Oncol; 2012 Oct; 14(10):1227-38. PubMed ID: 22946104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
    Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
    J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
    Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
    J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
    Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
    Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.